Most tumour-directed therapies only kill targeted cells, which can render some therapies inefficacious if a tumour lacks an appropriate target. Theranostic products are designed to destroy the tumour target plus adjacent tumour cells, regardless of their receptor or antigen profile.
The illustration below shows how theranostic products kill cancer cells. Traditional therapies target certain types of cancer cells but leave the rest behind to continue to grow. These cancer cells left behind often proliferate more aggressively than the original tumour.
Theranostic therapies, such as Telix’s therapies, have a killing distance that destroys a greater variety of cancer cells. They work by destroying the tumour’s “structural” cells and further inciting the immune system, such as attracting T cells, to become involved in the treatment response.
The difference in mechanisms between traditional and theranostic cancer therapies suggest that theranostic products could have synergistic effects with other therapies, such as anti-androgens (prostate cancer) or checkpoint inhibitors (renal/brain cancer) without an overlapping toxicity profile. This is an important part of Telix’s strategy – integrating with Standard Care.